Prescription medicine
Albuterol and budesonide Brand names: Airsupra
Albuterol and budesonide (Airsupra) is a prescription medicine with an FDA approval on record since 2023. No generic is listed; pharmacies paid $45.03 per gram (Airsupra 90-80 mcg inhaler) in the October 7, 2026 NADAC survey.
- No generic listed
Check it at the source: the albuterol and budesonide FDA label on DailyMed (effective September 18, 2025, AstraZeneca Pharmaceuticals LP); the NDA 214070 record on Drugs@FDA; every albuterol and budesonide label on DailyMed.
Highlights of the record
FDA label of September 18, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageAIRSUPRA is indicated for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in patients with asthma 18 years of age and older.
Forms and strengths
Aerosol (metered).
On the market
- Earliest approval on file
- January 10, 2023 Airsupra, Astrazeneca; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
- Last listed patent
- May 28, 2030 Airsupra aerosol; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- $45.03 per gram Airsupra 90-80 mcg inhaler
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- 1 since 2025 0 Class I among all firms' recalls; latest May 14, 2025
- FAERS reports
- 1,374 through July 30, 2026
What is albuterol and budesonide used for?
From the label: indications and usageAIRSUPRA is indicated for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in patients with asthma 18 years of age and older. AIRSUPRA is a combination of albuterol, a beta 2 -adrenergic agonist and budesonide, a corticosteroid, indicated for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in patients with asthma 18 years of age and older.
Conditions named in the indications of albuterol and budesonide's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: Corticosteroid and beta2-Adrenergic Agonist.
Source: FDA drug label (AIRSUPRA), AstraZeneca Pharmaceuticals LP, effective September 18, 2025 (SPL set e60aa9f9-5139-44df-b886-ebddc3c7eb13), via openFDA; the full label on DailyMed
Is there a generic for albuterol and budesonide (Airsupra)?
No generic albuterol and budesonide is approved (Drugs@FDA, October 8, 2026).
The Orange Book lists 1 patent for Airsupra aerosol, the last expiring on May 28, 2030. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2023 earliest approval on file
- 2030 last listed patent
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for albuterol and budesonide (Airsupra)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $45.03 per gram (Airsupra 90-80 mcg inhaler), up 3% from $43.84 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Airsupra 90-80 mcg inhaler (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Airsupra 90-80 mcg inhaler | Brand | $45.03 per gram | n/a | +3% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Has albuterol and budesonide been recalled?
The FDA's Enforcement Report lists 1 recall naming albuterol and budesonide since 2025: 0 Class I (the most serious), 1 Class II, 0 Class III; 1 still ongoing. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| May 14, 2025 | Class II | AsttraZeneca Pharmaceuticals LP | Defective delivery system |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the albuterol and budesonide label say about other medicines?
The albuterol and budesonide label names 9 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Atazanavir | drug interactions | Caution should be exercised when considering the co-administration of AIRSUPRA with long-term ketoconazole and other known strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) [see Warnings and Precautions (5.11) ]. |
| Clarithromycin | drug interactions | Caution should be exercised when considering the co-administration of AIRSUPRA with long-term ketoconazole and other known strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) [see Warnings and Precautions (5.11) ]. |
| Digoxin | drug interactions | Mean decreases of 16% and 22% in serum digoxin levels were demonstrated after single-dose intravenous and oral administration of albuterol, respectively, to normal volunteers who had received digoxin for 10 days. |
| Itraconazole | drug interactions | Caution should be exercised when considering the co-administration of AIRSUPRA with long-term ketoconazole and other known strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) [see Warnings and Precautions (5.11) ]. |
| Ketoconazole | drug interactions | After oral administration of ketoconazole, a strong inhibitor of CYP3A4, the mean plasma concentration of orally administered budesonide increased. |
| Nefazodone | drug interactions | Caution should be exercised when considering the co-administration of AIRSUPRA with long-term ketoconazole and other known strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) [see Warnings and Precautions (5.11) ]. |
| Nelfinavir | drug interactions | Caution should be exercised when considering the co-administration of AIRSUPRA with long-term ketoconazole and other known strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) [see Warnings and Precautions (5.11) ]. |
| Prednisone | warnings and precautions | Hypercorticism and Adrenal Suppression Budesonide, a component of AIRSUPRA, will often help control asthma symptoms with less suppression of hypothalamic-pituitary-adrenal (HPA) function than therapeutically equivalent oral doses of prednisone. |
| Ritonavir | drug interactions | Strong cytochrome P450 3A4 inhibitors (e.g. ritonavir): Use with caution. |
Source: FDA drug label (AIRSUPRA), AstraZeneca Pharmaceuticals LP, effective September 18, 2025 (SPL set e60aa9f9-5139-44df-b886-ebddc3c7eb13), via openFDA; the full label on DailyMed
What do FAERS reports show for albuterol and budesonide?
The FDA Adverse Event Reporting System holds 1,374 reports that list albuterol and budesonide among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 18 are coded as a death and 97 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as albuterol and budesonide?
9 other medicines are given the same way (respiratory (inhalation)) and in the same FDA class as albuterol and budesonide or labeled mainly for the same use (asthma), the same class first. Asthma lists all 37 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (respiratory (inhalation)) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Fluticasone and salmeterol | Asthma | 8 labelers | $1.07 per unit 100-50 | A presentation being discontinued |
| Fluticasone | Asthma | 1 labeler | $11.82 per gram 44 mcg inhaler | No current entry |
| Beclomethasone | Asthma | 2 labelers | $20.57 per gram 40 mcg | No current entry |
| Fluticasone and vilanterol | Asthma | none listed | $3.90 per unit 100-25 | No current entry |
| Mometasone | Asthma | none listed | $6.84 per gram 50 mcg inhaler | No current entry |
| Formoterol and mometasone | Asthma | none listed | $25.22 per gram 100 mcg-5 mcg inhaler | No current entry |
| Fluticasone and umeclidinium and vilanterol | Asthma | none listed | $11.12 per unit 100-62.5-25 | No current entry |
| Ciclesonide | Asthma | none listed | $42.97 per gram 160 mcg inhaler | No current entry |
Every medicine labeled for the same conditions as albuterol and budesonide
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Alternatives to albuterol and budesonide
- 9 medicines for the same use
- Other corticosteroids
- the pharmacologic class, with prices and generics
- Albuterol and budesonide side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other